Journal Article

DKFZ-2025-01898

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Targeting peroxiredoxin 2 prevents hepatocarcinogenesis in metabolic liver disease models.

Crouchet, E. ; Schaeffer, E. ; Oudot, M. A. ; Moehlin, J. ; Gadenne, C. ; Jühling, F. ; El Saghire, H. ; Fujiwara, N. ; Zhu, S. ; Akter Rasha, F. ; Durand, S. C. ; Charlot, A. ; Ponsolles, C. ; Martin, R. ; Brignon, N. ; Del Zompo, F. ; Meiss Heydmann, L. ; Parnot, M. ; Hamdane, N. ; Heide, D.DKFZ* ; Hetzer, J.DKFZ* ; Heikenwälder, M.DKFZ* ; Felli, E. ; Pessaux, P. ; Pochet, N. ; Zoll, J. ; Cunniff, B. ; Hoshida, Y. ; Mailly, L. ; Baumert, T. F. ; Schuster, C.

2025
ASCJ Ann Arbor, Mich.

This record in other databases:  

Please use a persistent id in citations: doi:10.1172/JCI169395

Abstract: Treatment options for advanced liver disease and hepatocellular carcinoma (HCC) are limited and strategies to prevent HCC development are lacking. Aiming to discover novel therapeutic targets, we combined genome wide transcriptomic analysis of liver tissues from patients with advanced liver disease and HCC and a cell-based system predicting liver disease progression and HCC risk. Computational analysis predicted peroxiredoxin 2 (PRDX2) as a candidate gene mediating hepatocarcinogenesis and HCC risk. Analysis of HCC patient tissues confirmed a perturbed expression of PRDX2 in cancer. In vivo perturbation studies in mouse models for MASH driven hepatocarcinogenesis showed that specific Prdx2 knockout in hepatocytes significantly improved metabolic liver functions, restored AMPK activity and prevented HCC development by suppressing oncogenic signaling. Perturbations studies in HCC cell lines, a CDX mouse model and patient-derived HCC spheroids unraveled that PRDX2 also mediates cancer initiation, cancer cell proliferation and survival through its antioxidant activity. Targeting PRDX2 may therefore be a valuable strategy to prevent HCC development in metabolic liver disease.

Keyword(s): Carbohydrate metabolism ; Hepatology ; Oncology ; Preventative medicine ; Therapeutics

Note: 2025 Sep 11;135(21):e169395

---

Contributing Institute(s):

1. Chronische Entzündung und Krebs (D440)

Research Program(s):

1. 314 - Immunologie und Krebs (POF4-314) (POF4-314)

Appears in the scientific report 2025

---

Database coverage:
; ; ; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF >= 15 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---